Expert Interview
Discussing Kezar’s Zetomipzomib trial in Lupus Nephritis following recently released phase 2 results
Ticker(s): KZRA nephrologist with experience treating Lupus Nephritis.
Please describe your clinical practice. How many patients with Lupus Nephritis do you see on a yearly basis? What is your opinion on the standard of care?
Added By: slingshot_insightsHow well do patients respond to treatment with steroids + mycophenolate mofetil / cyclophosphamide?
Could you talk to us about the unmet needs in this disease?
How does zetomipzomib’s subcutaneously once weekly method of administration compare?
Could you please tell us your thoughts on the Phase 2 results, where:-64.7% patients achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months- 35.2% achieved a complete renal response, including a UPCR of 0.5 or less at 6 months
Zetomipzomib appears to be immunomodulatory and steroid-sparing, according to the company’s Chief Medical Officer. How important is this aspect?
Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, could you walk us through the differences in comparison to other trials in LN?
How likely would you be to switch patients to Zetomipzomib?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
